Zealand Pharma A/S ( (ZLDPF) ) has released its Q1 earnings. Here is a breakdown of the information Zealand Pharma A/S presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of innovative peptide-based medicines, with a focus on obesity and inflammation treatments.
In the first quarter of 2025, Zealand Pharma reported significant progress in its clinical pipeline and organizational capabilities, highlighted by a transformative partnership with Roche to co-develop and co-commercialize petrelintide, a promising therapy for weight management. The company also appointed a new Chief Scientific Officer to lead its next wave of innovative medicines.
Key financial metrics for the quarter included a revenue of DKK 8 million, a decrease from the previous year, and operating expenses of DKK 393 million, driven by clinical advancements in its obesity pipeline. The company maintained a strong cash position of DKK 8.5 billion, which is expected to be bolstered by an upcoming USD 1.65 billion payment from Roche. Zealand Pharma also completed participant enrollment in the Phase 2 ZUPREME-1 trial and initiated the ZUPREME-2 trial for petrelintide.
Looking ahead, Zealand Pharma remains optimistic about its growth prospects, supported by its strategic partnership with Roche and ongoing clinical developments. The company plans to accelerate investments in its early-stage research pipeline, aiming to establish a leading position in peptide therapeutics targeting obesity and inflammation.